AMGEN Inc.

NASDAQ:AMGN   3:59:59 PM EDT
224.90
-2.26 (-1.00%)
Regulatory, Earnings Announcements

Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib

Published: 10/05/2020 20:56 GMT
Amgen Inc (AMGN) - Amgen Announces Positive Topline Phase 2 Results for Investigational Kras G12c Inhibitor Sotorasib in Advanced Non-small Cell Lung Cancer.
Amgen Inc - Durable Anticancer Activity Observed in Patients Whose Cancer Had Progressed Despite Prior Treatment With Chemotherapy And/or Immunotherapy.
Amgen Inc - Sotorasib Demonstrated an Objective Response Rate (primary End Point) Consistent With Previously Reported Phase 1 Data.
Amgen Inc - Safety and Tolerability for Sotorasib Were Similar to Previously Reported Data in Phase 1 in Patients With Advanced Nsclc.
Revenue is expected to be $6.38 Billion
Adjusted EPS is expected to be $3.80

Next Quarter Revenue Guidance is expected to be $6.63 Billion
Next Quarter EPS Guidance is expected to be $3.57

More details on our Analysts Page.